One of the prominent roles of a body's immune system is its ability to differentiate between normal cells and foreign cells like bacteria, viruses, germs, & even cancer cells. The immune system uses checkpoint proteins on the immune cells to attack the foreign cells without affecting the normal ones. The checkpoints behave like switches that turn on or off a response.
However, sometimes the cancer cells outwit the immune system and spread in the body. It is where immune checkpoint inhibitors come into the picture, where they use the body's immune system and turn it on to target the cancer cells. These inhibitors are known for attacking potentially harmful agents. In the case where immune response begins affecting healthy tissues, the system can be turned off in order to prevent the damage.
While immune checkpoint inhibitors do not kill the cancer cells directly, they find ways to help the immune system find & attack the cells throughout the body. With rapid advancements in checkpoint inhibitors, these proteins can now also be used for the treatment of a few cancers by infusing drugs into the vein.
The Global Immune Checkpoint Inhibitors Market is projected to grow at a CAGR of around 17% during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the rapidly increasing incidence of cancer worldwide & the mounting demand for effective & safe treatments, i.e., instigating governments to enhance the healthcare infrastructure to cater to the high unmet patient needs.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe|
|Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific|
|South America: Brazil, Rest of Latin America|
|Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa|
|Key Companies Profiled||
AstraZeneca PLC, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, NovartAbbVie Inc., Amgen Inc., AstraZeneca PLC, Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc. Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Othersis International AG, Pfizer Inc., Sanofi, Others
|Unit Denominations||USD Million/Billion|
In addition, since the advent of immune checkpoint inhibitors, cancer treatment has witnessed a revolution in the past years and even demonstrated alternation in outcomes for various cancers, including Malignant Melanoma & Non-Small Cell Lung Cancer. This aspect is playing a prominent role in instigating the leading biopharma companies to conduct rigorous research & development activities to bring innovations in immune checkpoint inhibitors and introduce novel drugs for greater efficacy & safety.
Besides, the growing adoption of immune checkpoint inhibitors for preventing cancer cells from turning off T lymphocytes (T cells) is also elevating their demand and augmenting the overall market growth. T cells are a kind of immune system cells that kill cancer and have receptors on their surfaces from where other cells stick & turn them on or off. In some cases, the cancer cells bind with the receptors on activated T cells and turn them off. However, immune checkpoint inhibitors prevent the cancer cells from doing so & allow T cells to infiltrate the tumor while eliminating its growth. Hence, due to such benefits, the demand for immune checkpoint inhibitors is rising rapidly for their application in various cancer treatments and stimulating the expansion of the global market.
Moreover, growing awareness among patients about their benefits, like fewer side effects & targeted therapeutic effects, is another prominent aspect contributing to the mounting demand for immune checkpoint inhibitors worldwide. It, in turn, is also attracting massive funding from various pharmaceuticals, biotech companies, universities, & cancer centers in the research & development of more effective immune checkpoint inhibitors and fueling the overall market growth.
Based on the Drug Class:
Of all drug classes, PD-1 inhibitors are anticipated to acquire the largest share in the Global Immune Checkpoint Inhibitors Market during 2022-27. It attributes principally to the massive government investments in various research & development activities for bringing innovations in PD-1 inhibitors like Opdivo (Nivolumab) & Keytruda (Pembrolizumab), coupled with rapid approvals from regulatory associations. Additionally, with the swift escalation in the influx of cancer patients, the prescription for Nivolumab & Pembrolizumab drugs are also rising and boosting the Global Immune Checkpoint Inhibitors Market.
Besides, with the approval of Pembrolizumab by the Food & Drug Association (FDA) owing to its efficiency in addressing indications like Melanoma, Non–Small Cell Lung Cancer (NSCLC), Head & Neck Squamous Cell Cancer (HNSCC), and others, the demand for PD-1 exhibiters has escalated swiftly, i.e., playing a prominent role in augmenting the overall market growth.
Furthermore, incidences of allergic reactions from other drug cases like CTLA-4 inhibitor, Yervoy (Ipilimumab), is another aspect demonstrating greater inclination of patients toward PD-1 and, in turn, promoting the expansion of the Immune Checkpoint Inhibitors Market globally.
On the other hand, CTLA-4 inhibitors are anticipated to demonstrate rapid market growth in the years ahead. It owes to the checkpoint protein inhibitor on T cells, which acts as an "off-switch" to keep the immune system in the best shape. To date, CTLA-4 has only one drug case, Yervoy (Ipilimumab), i.e., a monoclonal antibody, which enables the immune system to fight against cancer. While in some cases, depending upon the patient health conditions, Yervoy, in combination with PD-1 inhibitors, might be used for multiple cancer treatments, including melanoma.
Based on the Application:
Here, melanoma is anticipated to contribute significantly to the growth of the Global Immune Checkpoint Inhibitors Market during 2022-27, mainly due to the growing inclination of melanoma patients toward immunotherapy, i.e., surging the demand for immune checkpoint inhibitors that target the dysfunctional immune system to induce CD8-positive T cells and kill the cancer cells. The anti-CTLA4 & anti-PD-1 antibodies of the immune checkpoint inhibitors have shown positive patient outcomes in many cancers, including advanced melanoma, where these antibodies are likely in some patients today.
Even though adequate trial data have been missing, the combination of anti-CTLA4 & anti-PD-1 immune checkpoint inhibition in advanced melanoma cancer has shown the highest 5-year overall survival rate & high activity in cases of melanoma brain metastases. Hence, the application of immune checkpoint inhibitors is likely to notably soar in melanoma treatment and, in turn, drive the global market through 2027.
Geographically, the Global Immune Checkpoint Inhibitors Market expand across:
Of all regions globally, Asia-Pacific is anticipated to dominate the Immune Checkpoint Inhibitors Market with the largest share during 2022-27. It owes principally to massive healthcare expenditure by governments of different countries across the region, coupled with the active participation of the leading players in various research & development activities for bringing innovations in immune checkpoint inhibitors. Besides, with the growing influx of cancer patients across Asia-Pacific, the demand for therapies like immunotherapy, including immune checkpoint inhibitors, is rising rapidly, especially in China, Japan, & India.
Moreover, various prominent biopharma companies in the region are collaborating with local firms with a principal aim to increase their research, production, & distribution capacities while expanding product portfolio and offering a wide variety of effective inhibitors to patients. Hence, the Asia-Pacific Immune Checkpoint Inhibitors Market is set to grow substantially and generate lucrative prospects for the leading players in the coming years.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Global Immune Checkpoint Inhibitors Market is projected to grow at a CAGR of around 17% during 2022-27.
A. Growing awareness among patients about the effectiveness of immune checkpoint inhibitors in fighting cancer and eliminating its possibilities by turning the T-cells off is the most prominent factor driving the Global Immune Checkpoint Inhibitors Market.
A. PD-1 is anticipated to emerge as an area of remunerative opportunities for the leading players in the Global Immune Checkpoint Inhibitors Market over the forecast years.